Javascript must be enabled to continue!
Abstract 1211: Novel detection and characterization of truncated ERBB2 demonstrates potent oncogenicity of the p110 isoform in human mammary epithelial cells
View through CrossRef
Abstract
The full-length p185 ERBB2 (HER2) receptor tyrosine kinase is a validated target for breast cancer (BC) therapy. It is now appreciated that a portion of ERBB2+ BC expresses truncated isoforms of the receptor, including the membrane localized forms p95 and p110. Importantly, t-ERBB2s lack the extracellular domain epitope of trastuzumab and act as a resistance mechanism to therapy. Data from transgenic mouse models implicate expression of t-ERBB2s in tumor formation and metastasis. Furthermore, human clinical studies have revealed that expression of t-ERBB2s correlates with poor patient outcome, increased nodal involvement, and increased metastasis.
In this study, we used partially transformed breast epithelial cells (HMLEs) to extend the studies of t-ERBB2 expression in human cells. Stable expression of cDNAs coding for p110 t-ERBB2 led to increased migration (79 cells/ well versus 39, p = 0.04), and invasion (583 cell/ well vs. 290) p = 0.03) of p110 versus p185 expressing HMLE cells, respectively. Importantly, expression of p110 t-ERBB2, but not other isoforms, led to xenograft formation by HMLE cells in NOD/SCID mice (p110, 10 of 12 possible xenografts formed, p185, no xenografts formed).
Accurate clinical profiling of t-ERBB2 expression may aid in selection of ERBB2-targeted therapy. To this end, we used a novel proximity-mediated immunoassay (CoPIA) to detect and quantify t-ERBB2 receptors in patient samples. Analysis of a cohort of 74 primary breast tumors revealed that 52% of breast tumor samples with a high ERBB2-IHC score (3+) contained t-ERBB2, with 32% containing phosphorylated t-ERBB2. In several samples t-ERBB2 accounted for 10-20% of the total ERBB2 receptor population in tumor cells. Finally, fine-needle aspirates of ERBB2+ metastases also revealed expression and phosphorylation of t-ERBB2s.
In addition to its role in prognosis and therapeutic guidance, p110 t-ERBB2 represents an attractive target for therapy. We have generated several mouse monoclonal antibodies targeting the N-termini of p110 t-ERBB2s. Binding of p110 on the surface of living cells was assayed by flow cytometry, and the biological activity of these antibodies is currently being assessed in vitro and in vivo.
Together, these data imply a functional role for the p110 t-ERBB2 isoform in tumorigenesis, invasion, and migration. Furthermore, expression of t-ERBB2 in the majority of IHC 3+ tumor samples reveals a significant incidence of t-ERBB2 in human cancers. Targeting of p110 t-ERBB2 may allow for novel therapeutic intervention in ERBB2+ primary and metastatic breast cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1211. doi:10.1158/1538-7445.AM2011-1211
American Association for Cancer Research (AACR)
Title: Abstract 1211: Novel detection and characterization of truncated ERBB2 demonstrates potent oncogenicity of the p110 isoform in human mammary epithelial cells
Description:
Abstract
The full-length p185 ERBB2 (HER2) receptor tyrosine kinase is a validated target for breast cancer (BC) therapy.
It is now appreciated that a portion of ERBB2+ BC expresses truncated isoforms of the receptor, including the membrane localized forms p95 and p110.
Importantly, t-ERBB2s lack the extracellular domain epitope of trastuzumab and act as a resistance mechanism to therapy.
Data from transgenic mouse models implicate expression of t-ERBB2s in tumor formation and metastasis.
Furthermore, human clinical studies have revealed that expression of t-ERBB2s correlates with poor patient outcome, increased nodal involvement, and increased metastasis.
In this study, we used partially transformed breast epithelial cells (HMLEs) to extend the studies of t-ERBB2 expression in human cells.
Stable expression of cDNAs coding for p110 t-ERBB2 led to increased migration (79 cells/ well versus 39, p = 0.
04), and invasion (583 cell/ well vs.
290) p = 0.
03) of p110 versus p185 expressing HMLE cells, respectively.
Importantly, expression of p110 t-ERBB2, but not other isoforms, led to xenograft formation by HMLE cells in NOD/SCID mice (p110, 10 of 12 possible xenografts formed, p185, no xenografts formed).
Accurate clinical profiling of t-ERBB2 expression may aid in selection of ERBB2-targeted therapy.
To this end, we used a novel proximity-mediated immunoassay (CoPIA) to detect and quantify t-ERBB2 receptors in patient samples.
Analysis of a cohort of 74 primary breast tumors revealed that 52% of breast tumor samples with a high ERBB2-IHC score (3+) contained t-ERBB2, with 32% containing phosphorylated t-ERBB2.
In several samples t-ERBB2 accounted for 10-20% of the total ERBB2 receptor population in tumor cells.
Finally, fine-needle aspirates of ERBB2+ metastases also revealed expression and phosphorylation of t-ERBB2s.
In addition to its role in prognosis and therapeutic guidance, p110 t-ERBB2 represents an attractive target for therapy.
We have generated several mouse monoclonal antibodies targeting the N-termini of p110 t-ERBB2s.
Binding of p110 on the surface of living cells was assayed by flow cytometry, and the biological activity of these antibodies is currently being assessed in vitro and in vivo.
Together, these data imply a functional role for the p110 t-ERBB2 isoform in tumorigenesis, invasion, and migration.
Furthermore, expression of t-ERBB2 in the majority of IHC 3+ tumor samples reveals a significant incidence of t-ERBB2 in human cancers.
Targeting of p110 t-ERBB2 may allow for novel therapeutic intervention in ERBB2+ primary and metastatic breast cancer.
Citation Format: {Authors}.
{Abstract title} [abstract].
In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL.
Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1211.
doi:10.
1158/1538-7445.
AM2011-1211.
Related Results
Investigations into the puerperium of Beagle-breed female dogs
Investigations into the puerperium of Beagle-breed female dogs
The present thesis focusses on the study of the puerperium of female dogs, with the general objective to increase available knowledge regarding the puerperium of that species and t...
Abstract P5-06-03: Truncated ERBB2 Receptors: Diagnostic and Therapeutic Targets
Abstract P5-06-03: Truncated ERBB2 Receptors: Diagnostic and Therapeutic Targets
Abstract
Background:
Patients with ERBB2+ breast cancer have aggressive disease and poor prognoses. It is now apparent that many ERBB2+ tumors also ex...
P2-01-25: Truncated p110 ERBB2 (CTF611) Increases Migration and Invasion of Breast Epithelial Cells by Inhibiting STAT5b Activation.
P2-01-25: Truncated p110 ERBB2 (CTF611) Increases Migration and Invasion of Breast Epithelial Cells by Inhibiting STAT5b Activation.
Abstract
Background: Truncated ERBB2 receptors are present in a subset of human ERBB2+ amplified/overexpressing breast tumors, and are associated with trastuzumab re...
Embryonic Mammary Gland Development
Embryonic Mammary Gland Development
AbstractMammary glands are derived from the ectoderm and are a defining feature of mammals. The number of glands that develop along the ‘mammary lines’ on either side of the ventra...
Abstract 1331: The BK5.erbB2 mouse as a novel model of esophageal adenocarcinoma
Abstract 1331: The BK5.erbB2 mouse as a novel model of esophageal adenocarcinoma
Abstract
The incidence of esophageal adenocarcinoma (EAC) is rising rapidly throughout the Western world, and is associated with gastroesophageal reflux disease (GER...
Abstract 1823: Novel regulation of Jagged1 by ErbB2 in breast cancer: implications for anti-ErbB2 therapy
Abstract 1823: Novel regulation of Jagged1 by ErbB2 in breast cancer: implications for anti-ErbB2 therapy
Abstract
We have demonstrated that Notch1 is required for trastuzumab resistance in ErbB2 positive breast cancer. This indicates that ErbB2 suppresses Notch1 in brea...
Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways
Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways
Abstract
Background
c-erbB2, a proto-oncogene coding epidermal growth factor receptor-like receptor, also as a chemosensitivity/prognosis marker ...
Abstract 6519: Haploinsufficiency for BRCA2 leads to common fragile site instability in human mammary epithelial cells
Abstract 6519: Haploinsufficiency for BRCA2 leads to common fragile site instability in human mammary epithelial cells
Abstract
Individuals with germline heterozygous mutations of breast cancer susceptibility genes BRCA1 or BRCA2 have a 50 to 80% lifetime risk of developing breast ca...

